SPY767.05 QQQ687.90−0.59%BTC/USD80,420.46−0.01%DIA535.58+0.46%GLD378.03+1.49%TLT82.03+0.33%

Premium Services

EVOFEM BIOSCIENCE INC by Evofem Biosciences, Inc.

EVFMOTCID

Trade with Public

Trade with Public

$0.4782

-77.52-99.39%

Last update: Nov 4, 3:52 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

EVOFEM BIOSCIENCE INC by Evofem Biosciences, Inc. (EVFM) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for EVOFEM BIOSCIENCE INC by Evofem Biosciences, Inc. (EVFM) stock.

Analyst Consensus — 1 Analysts

1Hold

# Analysts1

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for EVOFEM BIOSCIENCE INC by Evofem Biosciences, Inc. Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Dec 13, 2023	Laidlaw & Co.	Yale Jen	Downgrade	Buy→Hold	—

Analyst Ratings News

PRO
Laidlaw & Co. Downgrades Evofem Biosciences to Hold

Laidlaw & Co. analyst Yale Jen downgrades Evofem Biosciences (OTC:EVFM) from Buy to Hold.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022

Benzinga Insights

PRO
Stifel Downgrades Evofem Biosciences to Hold, Lowers Price Target to $0.5

Stifel analyst Annabel Samimy downgrades Evofem Biosciences (OTC:EVFM) from Buy to Hold and lowers the price target from $3 to $0.5.

Benzinga Newsdesk

4 Analysts Have This to Say About Evofem Biosciences

Over the past 3 months, 4 analysts have published their opinion on Evofem Biosciences (OTC:EVFM) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga Insights

PRO
HC Wainwright & Co. Maintains Buy on Evofem Biosciences, Raises Price Target to $4

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Evofem Biosciences (OTC:EVFM) with a Buy and raises the price target from $2 to $4.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Underweight on Evofem Biosciences, Lowers Price Target to $0.75

Morgan Stanley analyst Jeffrey Hung maintains Evofem Biosciences (NASDAQ:EVFM) with a Underweight and lowers the price target from $2 to $0.75.

Benzinga Newsdesk